CannabisNewsBreaks – Willow Biosciences Inc. (CSE: WLLW) Releases Q2 2019 Results and Provides Operational Update

August 30, 2019 13:49:07

Willow Biosciences (CSE: WLLW) today released its financial results for the three and six months ended June 30, 2019 and provided an operational update. Among highlights for the quarter, the company reported that it has: expanded its operations to include three facilities located in Calgary, Alberta, Mountain View, California and Burnaby, British Columbia; made key appointments to its management team and board of directors; entered an exclusive Joint Development Agreement (“JDA”) with Noramco; and completed a reverse takeover and raised gross proceeds of approximately $37.0 million. “Over the past few months, we have made impressive progress in advancing our business on several important fronts,” Willow President and Chief Executive Officer Trevor Peters said in the news release. “We have assembled a team of proven business executives and world-renowned scientists to lead the development of our high-quality consumer, wellness, and pharmaceutical ingredient manufacturing programs. The development of our yeast-based cannabinoid production platform is progressing well and we expect to initiate the scaling up of our process in the first half of 2020. In addition to advancing our development operations, we are focused on positioning Willow for successful future commercialization through our recently signed strategic partnership with Noramco, Inc. (Noramco), one of the world’s leading pharmaceutical cannabinoid ingredient producers.”

To view the full press release, visit

About Willow Biosciences Inc.

Headquartered in Calgary, Canada, Willow and its team of scientists are leaders in the field of biosynthetic production of high-value, plant-derived compounds. Willow has applied its integrated suite of technologies to develop manufacturing processes for numerous active pharmaceutical ingredients with various therapeutic benefits, including cancer treatment, pain management and CNS disorders. In the cannabinoid field, Willow owns proprietary, yeast-based lab strains that produce CBD, tetrahydrocannabinol (THC) and cannabigerol (CBG), as well as certain minor and novel cannabinoids. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
905.674.5977 Office